<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04967976</url>
  </required_header>
  <id_info>
    <org_study_id>E20210210</org_study_id>
    <nct_id>NCT04967976</nct_id>
  </id_info>
  <brief_title>Breast Mesh Used in Two-staged Breast Reconstruction</brief_title>
  <official_title>A Prospective Randomized and Controlled Study of Efficacy and Safety of TiLOOP® Bra Mesh in Patients With Expander-Implant Breast Reconstruction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first prospective randomized and controlled study on the efficacy and safety of&#xD;
      TiLOOP® Bra mesh in patients with expander-implant breast reconstruction. The investigators&#xD;
      hypothesize that incoporating TiLOOP Bra mesh with tissue expanders will reduce the rates of&#xD;
      capsular contraction, improve the efficiency of expansion and provide better aesthetic&#xD;
      result.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complication Rates</measure>
    <time_frame>up to 24 months after surgery</time_frame>
    <description>complications related to the reconstructed breast, including flap complications, capsular contracture, surgical site infection, prosthetic malposition/extrusion, reconstruction failure, etc.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expansion Efficiency</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>percentage of average injected saline volume to total volume (E=average volume/ total volume）through study completion, an average of 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of revision surgery</measure>
    <time_frame>from the completion of expander exchange up to 24 months after surgery</time_frame>
    <description>To record the rate of surgical revision events on the breast including but not limited to fat tranplantation, reduction mammoplasty/mastompexy, contralateral augmentation,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aesthetic outcome graded by Harris evaluation score and Breast-Q questionaire</measure>
    <time_frame>from the completion of expander exchange up to 24 months after surgery</time_frame>
    <description>Harris evaluation score was used to evaluate the aesthetic outcome of patients' reconstructed breasts, which was scored as &quot;excellent,&quot; &quot;good,&quot; &quot;fair,&quot; &quot;poor&quot;.&#xD;
Breast-Q questionaire was also used to evaluate the aesthetic outcome of patients' reconstructed breast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>psychological evaluation by Breast-Q questionnaire</measure>
    <time_frame>from the completion of expander exchange up to 24 months after surgery</time_frame>
    <description>We use the Breast-Q questionnaire to evaluate patients' satisfaction via the reconstruction module of BREAST-Q.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total cost</measure>
    <time_frame>from expander implation up to the completion of expander exchange,through study completion, an average of 1 year</time_frame>
    <description>total cost in RMB per captia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of occurrence of deep venous thrombosis</measure>
    <time_frame>from expander implation up to the completion of expander exchange, through study completion, an average of 1 year</time_frame>
    <description>post-operative occurrence of deep venous thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of occurrence of non-surgical site infection</measure>
    <time_frame>from expander implation up to the completion of expander exchange, through study completion, an average of 1 year</time_frame>
    <description>post-operative occurrence of non-surgical site infection including but not limited pneumonia, urinary tract infection, etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Radiation</condition>
  <condition>Breast Reconstruction</condition>
  <condition>Synthetic Mesh</condition>
  <arm_group>
    <arm_group_label>Breast Reconstruction with breast mesh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The tissue expander-implant reconstruction with TiLoop Bra mesh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast Reconstruction without breast mesh</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The tissue expander-implant reconstruction without TiLoop Bra mesh. The tissue expander is placed sub-pectoral and covered by muscle/fascia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TiLoop Bra mesh in expander-implant breast reconstrution</intervention_name>
    <description>The tissue expander is inserted with TiLoop Bra mesh in the first stage of reconstruction immediately after nipple/skin-sparing mastectomy. The tissue expander is placed sub-pectoral.</description>
    <arm_group_label>Breast Reconstruction with breast mesh</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sub-pectoral expander-implant breast reconstruction</intervention_name>
    <description>The tissue expander is inserted without TiLoop Bra mesh in the first stage of reconstruction immediately after nipple/skin-sparing mastectomy. The tissue expander is placed sub-pectoral and covered by muscle/fascia.</description>
    <arm_group_label>Breast Reconstruction without breast mesh</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with breast cancer&#xD;
&#xD;
          2. More than 18 years old&#xD;
&#xD;
          3. Karnofsky Performance Status (KPS) larger than 80&#xD;
&#xD;
          4. No clinical or imaging evidence of distant metastasis&#xD;
&#xD;
          5. BMI &lt; 35kg/m2&#xD;
&#xD;
          6. Patients with no or mild breast ptosis&#xD;
&#xD;
          7. No severe deficiency in hematological, cardiovascular system, no immune-deficiency, no&#xD;
             severe abnormal liver or kidney function.&#xD;
&#xD;
          8. Mental Health Patient&#xD;
&#xD;
             -&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
        1. Patients with distant metastasis of breast cancer or local recurrence; 2. Past&#xD;
        ipsilateral breast/chest wall radiation; 3. Inflammatory breast cancer, stage IV breast&#xD;
        cancer 4. History of severe allergic or specific constitution; 5. Mental illness; 6.&#xD;
        Drug/alcohol abuse; 7. Pregnancy, lactation, or impregnated during the trial period; 8.&#xD;
        Non-eligible to the study enrollment based on researchers' discretion&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jian Yin</last_name>
    <phone>+86-22-23340123</phone>
    <phone_ext>1174</phone_ext>
    <email>yinjian@tjmuch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bowen Ding</last_name>
    <phone>+86-22-23340123</phone>
    <phone_ext>1171</phone_ext>
    <email>ding_x87@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Chang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gansu Provincial Cancer Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suisheng Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Ch'ang-ch'un</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guiying Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bowen Ding</last_name>
      <phone>18822077799</phone>
      <email>ding_x87@126.com</email>
    </contact>
    <investigator>
      <last_name>Jian Yin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bowen Ding</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuli Meng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Technical University of Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Paepke</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>breast reconstruction</keyword>
  <keyword>radiation</keyword>
  <keyword>synthetic mesh</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

